30 closest matches · ranked by relevance
Thrombocythemia, Hemorrhagic
Primary: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time — 66.4; 66.9; 0.5; -1.1 percentage of ejection fraction
Atherosclerosis
Primary: Carotid Artery Stiffness (Expressed by Beta-stiffness Index ) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From…
High Risk Polycythemia Vera · High Risk Essential Thrombocythemia
Primary: Number of Participants With Complete Remission (CR) — 17; 19; 12; 13 Participants
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Participants With a Platelet Response — 12; 0 Participants
Essential Thrombocythemia
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 73 Participants
Essential Thrombocythemia (ET)
Primary: Percentage of Subjects Who Responded in Platelet Count — 67.9 percentage of subjects
Acute Myeloid Leukemia · Essential Thrombocythemia
Primary: Recommended Phase 2 Dose of LY573636-Sodium in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Essential Thrombocythemia (ET)
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Essential Thrombocythemia (ET)
Primary: Number of Participants Who Had One or More Adverse Events — 776 Participants
Blood Platelet Disorders
Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants
Myeloproliferative Diseases
Primary: Number of Patients With Objective Responses (Complete, Major, Moderate or Minor Responses), in Terms of Best Overall Response — 2; 12; 2; 1 Participants
Thrombocytopenia
Primary: Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study — 1; 6; 12; 9 Participants…
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Primary Myelofibrosis (MF)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 50; 46; 12; 5 Participants
Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 7; 1 Participants
Essential Thrombocythemia (ET)
Primary: Change From Baseline in Platelet Count at Final Assessment — 1021.6; -346.2 10^9 platelets per liter (10^9/L)
Leukemia · Chronic Myelogenous Leukemia · Chronic Myeloid Leukemia
Primary: Number of Participants With Complete Response — 3 Participants
Myelofibrosis · Polycythemia Vera · Thrombocytosis
Primary: Number of Participants With Adverse Events (AEs) — 30; 35; 47; 5 participants
Myeloproliferative Disorders
Primary: Number of Patients With Complete Response (CR) or Partial Response (PR) — 3; 3; 14; 23 Participants
Chronic Myelomonocytic Leukemia · Chronic Myeloid Leukemia · Polycythemia Vera
Primary: Number of Participants With a Complete Response (CR) — 0; 0; 2; 0 participants
Thrombocytopenia · MDS · Myelodysplastic Syndromes
Primary: Part A: Number of Participants With Adverse Events — 6; 11; 11; 15 Participants
MPN (Myeloproliferative Neoplasms)
Primary: Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose — -11.6; -17.4; -22.4; -13.4 Percentage change from baseline — p=0.0250
Essential Thrombocythaemia
Primary: Maximum Plasma Concentration (Cmax) of Agrylin — 2.66; 3.63 ng/ml — p=0.092
Thrombocytopenia · Hematologic Diseases
Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 4; 4 Participants
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities — 73; 62; 36; 16 Participants
Thrombocytopenia · Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants With Collagen Fibrosis — 0.0; 0.0; 3.4 percentage of participants
Idiopathic Thrombocytopenic Purpura
Primary: Weeks With Weekly Platelet Response — 0.0; 11.0 Weeks — p=<0.0001
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Percentage of Participants With a Durable Platelet Response — 10.0; 52.4 percentage of participants — p=0.0018
Myelofibrosis
Primary: Objective Response Rate (ORR) — 1; 9; 1 Participants